NP1192 是一种高效、选择性的 PROTAC NAT10 降解剂,可降低癌细胞中 NAT10 蛋白的表达并抑制 ac4C 修饰,通过破坏 NAT10/HIF-1α/PD-L1 轴实现对缺氧驱动的糖酵解和免疫抑制的双重抑制,在体外和体内均展现出卓越的抗肿瘤功效,并与抗 PD-L1 联合产生协同作用,可用于卵巢癌、宫颈癌、胶质母细胞瘤相关研究(粉色:NAT10 配体 (MS-Q75026);蓝色:Cereblon 配体 (MS-I68957);黑色:连接子)。
产品编号: MS-W40368 CAS No.: 2966791-41-1 分子式: C39H42N8O5S 分子量: 734.87
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

NP1192 是一种高效、选择性的 PROTAC NAT10 降解剂,可降低癌细胞中 NAT10 蛋白的表达并抑制 ac4C 修饰,通过破坏 NAT10/HIF-1α/PD-L1 轴实现对缺氧驱动的糖酵解和免疫抑制的双重抑制,在体外和体内均展现出卓越的抗肿瘤功效,并与抗 PD-L1 联合产生协同作用,可用于卵巢癌、宫颈癌、胶质母细胞瘤相关研究(粉色:NAT10 配体 (MS-Q75026);蓝色:Cereblon 配体 (MS-I68957);黑色:连接子)。

生物实验数据

生物活性 NP1192 is a highly potent and selective PROTAC NAT10 degrader that reduces NAT10 protein expression and inhibits ac4C modification in cancer cells, achieves dual inhibition of hypoxia-driven glycolysis and immunosuppression by disrupting the NAT10/HIF-1α/PD-L1 axis, exhibits superior antitumor efficacy both in vitro and in vivo, produces synergistic effects in combination with anti-PD-L1, and can be used for research on ovarian cancer, cervical cancer, and glioblastoma (Pink: NAT10 ligand (MS-Q75026); Blue: Cereblon ligand (MS-I68957); Black: linker).
IC50 & Target

NAT10

 

体外研究
(In Vitro)

NP1192 (0-20 μM,24-48 小时) 以剂量和时间依赖的方式诱导 SiHa (人) 和 U14 (鼠) 宫颈癌细胞系中 NAT10 的降解,该过程通过泛素-蛋白酶体系统 (UPS) 而非溶酶体途径进行。
NP1192 (36 小时) 抑制宫颈癌 (SiHa) 细胞的生长,IC50 值为 7.814 μM (耐药细胞中为 76.2 μM),并且在类器官中也显示出剂量依赖性疗效,卵巢癌 (OV)、宫颈癌 (CESC) 和胶质母细胞瘤 (GBM) 类器官的 IC50 值分别为 9.947、3.048 和 13.76 μM。
NP1192 (20 μM,0-72 小时和 2 周) 显著降低宫颈细胞的活力,诱导细胞周期阻滞,并抑制其侵袭和克隆形成能力。
NP1192 (0.195-50 μM,1-8 天) 可显著减少肿瘤模型 (卵巢癌、宫颈癌和胶质母细胞瘤) 类器官的大小和数量,而相应的正常类器官则未受影响,表明其对非恶性组织的细胞毒性极低。
NP1192 (20 μM,36 小时) 通过降解 NAT10 进而损害 HIF-1α 的表达,重编程宫颈癌细胞的缺氧肿瘤微环境与代谢,其表现为葡萄糖摄取和乳酸生成减少以及 ATP 水平升高,从而破坏糖酵解过程。

Western Blot Analysis

Cell Line: SiHa, U14, and HFF-1 cells
Concentration: 0, 1.25, 2.5, 5, 10 and 20 μM
Incubation Time: 24, 36 and 48 h
Result: Led to a substantial depletion of total NAT10 protein in SiHa (human) and U14 (murine) CCa cell lines in a a dose-and time-dependent manner.
Induced degradation rates of 28%, 32%, 40%, and 43% in SiHa cells at concentrations of 1.25, 2.5, 5, and 10 μM, respectively, with a maximum of 69% degradation at 20 μM after 36 h and only 20% degradation after 24 h.
Led to a nearly 70% reduction in the NAT10 protein content in murine U14 cervical cells after 36 h.
Did not exhibit the classical hook effect even at concentrations as high as 20 μM.
Failed to degrade NAT10 significantly when co-treated with MG132 (MS-L06849), whereas Bafilomycin A1 (MS-R94699) exerted no discernible effect on its degradation efficacy.
Substantially induced minimal cytotoxicity in nonmalignant HFF-1 cells with low NAT10 expression.
Decreased HIF-1α protein levels.
Reversed the induction of hypoxia-related genes under hypoxic conditions, such as HIF1A and PD-L1, at both mRNA and protein levels.

Cell Proliferation Assay

Cell Line: SiHa cells and NAT10-KD SiHa cells
Concentration: 20 μM
Incubation Time: 2 weeks
Result: Led to a substantial decrease in colony formation capacity, with the magnitude of inhibition being only second to that in NAT10-knockdown cells.

Cell Invasion Assay

Cell Line: SiHa cells and NAT10-KD SiHa cells
Concentration: 20 μM
Incubation Time: 36 h
Result: Substantially hindered cell invasion with a significant decrease in the number of cells crossing the basement membrane.
体内研究
(In Vivo)

NP1192 (25 mg/kg,腹腔注射,每 2 天一次,持续一周) 可与抗 PD-L1 抗体协同作用,在 U14-luc 异种移植小鼠模型中抑制肿瘤生长、抑制糖酵解并增强 CD8+ T 效应细胞免疫功能。

Animal Model: Female C57BL/6J mice (6-8 weeks old) subcutaneously injected with U14-luc cells
Dosage: 25 mg/kg
Administration: i.p., every 2 days for a week
Result: Significantly reduced tumor volume and tumor burden compared to DMSO at 25 mg/kg.
Significantly inhibited tumor growth when combined with anti-PD-L1 antibody (2.5 mg/kg).
Showed the most pronounced reduction (>80%) in tumor lactate levels when combined with anti-PD-L1 antibody (2.5 mg/kg).
¹⁸F-FDG PET–CT imaging revealed minimal metabolic uptake when combined with anti-PD-L1 antibody, suggesting effective suppresses tumor metabolic activity.
Enhanced the CD8+ Teff cell population, reprograms the TME, and potentiates antitumor immunity when combined with anti-PD-L1 blockade.
Did not cause significant weight loss or systemic toxicity both alone and in combination.

化学信息

分子量 734.87
分子式 C39H42N8O5S
CAS No. 2966791-41-1

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础